(Total Views: 175)
Posted On: 03/28/2022 8:12:15 AM
Post# of 103492
NASDAQ : $AVCO News : Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies.
Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.
The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate.
https://finance.yahoo.com/news/avalon-globoca...tml?p=AVCO
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies.
Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.
The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate.
https://finance.yahoo.com/news/avalon-globoca...tml?p=AVCO
(0)
(0)Scroll down for more posts ▼
